Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: microRNA therapeutics - Viridian Therapeutics

Next Previous
Search
Drug Profile

Research programme: microRNA therapeutics - Viridian Therapeutics

Alternative Names: AntimiR-15; AntimiR-155; AntimiR-208; AntimiRNA-15; LNA antimiR; MGN 7455; MGN-4893; mimics of the microRNA-183/96/182 - Viridian Therapeutics; miR-143/145; miR-15/195; miR-206; miR-208; miR-208/499; miR-29; miR-499; miR-92/126; miR-92a; MIRG-9103; miRNA-145 inhibitor; MRG-107

Latest Information Update: 02 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Servier; University of Glasgow; University of Texas Southwestern Medical Center; Viridian Therapeutics
  • Class Cardiovascular therapies; Eye disorder therapies; MicroRNAs; Neuroprotectants
  • Mechanism of Action MicroRNA inhibitors; MIRN145-microRNA-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Cardiovascular disorders; Coronary artery restenosis; Fibrosis; Heart failure; Hypertrophic cardiomyopathy; Ischaemia; Polycythaemia vera; Postmyocardial infarction; Pulmonary arterial hypertension; Retinal disorders

Most Recent Events

  • 02 Jul 2024 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (Parenteral) prior to July 2024 (Viridian Therapeutics pipeline, July 2024) (Servier pipeline, July 2024)
  • 02 Jul 2024 Discontinued - Preclinical for Cardiovascular disorders in USA (Parenteral) prior to July 2024 (Viridian Therapeutics pipeline, July 2024) (Servier pipeline, July 2024)
  • 02 Jul 2024 Discontinued - Preclinical for Heart failure in USA (Parenteral) prior to July 2024 (Viridian Therapeutics pipeline, July 2024) (Servier pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top